查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
猴痘治療的全球市場:市場規模 - 各治療，各產品類型，各劑型，各給藥途徑，各年齡，性別，各處方類型，各終端用戶，各地區展望，競爭策略，各市場區隔預測(～2032年)
市場調查報告書
商品編碼
1208370

猴痘治療的全球市場:市場規模 - 各治療，各產品類型，各劑型，各給藥途徑，各年齡，性別，各處方類型，各終端用戶，各地區展望，競爭策略，各市場區隔預測(～2032年)

Monkeypox Treatment Market Size- By Treatment, By Product Type, By Dosage Form, By Route of Administration, By Age, By Gender, By Prescription Type, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2032
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 248 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球猴痘治療的市場規模，預計至2032年達到2億3,000萬美元，以10.37％的年複合成長率成長。全球猴痘病例增加，是促進市場收益成長的主要原因。

本報告提供全球猴痘治療市場相關調查，市場動態，市場變數與展望，各治療、產品類型、劑型、給藥途徑、年齡、性、處方類型、終端用戶、地區的市場分析，企業簡介等相關資訊。

目錄

第1章 簡介

  • 調查範圍
  • 市場區隔分析

第2章 調查手法

  • 調查資料來源
  • 市場規模的估計
  • 資料的三角測量

第3章 摘要整理

第4章 市場動態

  • 促進因素，阻礙因素，機會，課題的分析
    • 促進因素
    • 阻礙因素
    • 機會
    • 課題
  • 全球猴痘治療市場上COVID-19的影響

第5章 市場變數與展望

  • SWOT分析
    • 優勢
    • 弱點
    • 機會
    • 威脅
  • PESTEL分析
    • 政治形勢
    • 經濟形勢
    • 社會形勢
    • 技術形勢
    • 環境形勢
    • 法律上的形勢
  • 波特的五力分析
    • 供給企業談判力
    • 買方議價能力
    • 替代品的威脅
    • 新加入廠商的威脅
    • 競爭企業間的敵對關係
  • 熱圖分析

第6章 競爭情形

  • 全球猴痘治療的製造地流通，銷售區域，產品類型
  • 全球猴痘治療市場的合併、收購，夥伴關係，產品的銷售，合作

第7章 全球猴痘治療市場:各治療(2019年～2032年(100萬美元))

  • 藥物療法
    • 止痛藥
    • 停鎮護者癢劑、癢
    • 解熱止痛藥
    • 抗病毒藥物
  • 疫苗
    • 天花疫苗
    • JYNNEOS/Imvanex
  • 牛痘免疫球蛋白(VIG)

第8章 全球猴痘治療市場:各產品類型(2019年～2032年(100萬美元))

  • 乳霜
  • 凝膠
  • 注射劑
  • 軟膏
  • 錠劑

第9章 全球猴痘治療市場:各劑型(2019年～2032年(100萬美元))

  • 液體
  • 半固體
  • 固體

第10章 全球猴痘治療市場:各給藥途徑(2019年～2032年(100萬美元))

  • 口服
  • 非口服
  • 局部

第11章 全球猴痘治療市場:各年齡(2019年～2032年(100萬美元))

  • 成人
  • 老人
  • 兒童

第12章 全球猴痘治療市場:性別(2019年～2032年(100萬美元))

  • 女性
  • 男性
  • 其他

第13章 全球猴痘治療市場:各處方類型(2019年～2032年(100萬美元))

  • OTC(一般用醫藥品)
  • Rx(處方箋醫藥品)

第14章 全球猴痘治療市場:各終端用戶(2019年～2032年(100萬美元))

  • 醫院藥局
  • 線上藥局
  • 零售藥局

第15章 全球猴痘治療市場:各地區(2019年～2032年(100萬美元))

  • 全球猴痘治療的規模、市場佔有率:各地區(2019年～2025年)
  • 全球猴痘治療的規模、市場佔有率:各地區(2026年～2032年)
  • 亞太地區
    • 澳洲
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他的亞太地區
  • 歐洲
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
    • 其他的歐洲
  • 中東、非洲
    • 沙烏地阿拉伯王國
    • 阿拉伯聯合大公國
    • 其他的中東、非洲
  • 北美
    • 加拿大
    • 墨西哥
    • 美國
  • 南美
    • 阿根廷
    • 巴西
    • 其他的南美

第16章 企業簡介

  • Bavarian Nordic
    • 企業概要
    • 財務展望
    • 產品概要
    • 最近的開發
  • Chimerix
  • CIDIC Co., Ltd.
  • EMERGENT
  • Hetero
  • Olon S.p.A
  • Piramal Pharma Solutions
  • SIGA Technologies
  • Teva Pharmaceutical Industries Ltd.

第17章 簡稱一覽

第18章 參照鏈接

第19章 結論

第20章 調查範圍

簡介目錄
Product Code: HLCA2303

Global Monkeypox Treatment Market Overview

According to SPER Market Research, the Global Monkeypox Treatment Market is estimated to reach USD 0.23 billion by 2032 with a CAGR of 10.37%.

The monkeypox virus is the source of this uncommon but severe illness. Since monkey pox is a contagious disease, it can be spread by sick people, animals, or even contaminated objects. The monkeypox virus results in skin lesions and rashes on every part of the diseased body. Monkeypox symptoms and signs include fever, swollen lymph nodes, aches and chills, and muscle pain.

The market for monkeypox is anticipated to grow quickly in terms of CAGR. The increase in monkeypox cases worldwide is the main factor driving monkeypox market revenue growth.One of the main factors propelling the growth of the monkeypox market is the increase in monkeypox prevalence as a result of the rise in viral infections brought on by the monkeypox virus. The monkeypox virus can cause viral infection in people with weakened immune systems. Increase in numerous chronic illnesses and dermatological conditions like eczema, which causes weakened immunity and increases the risk of contracting the monkeypox virus, leads to the expansion of the monkeypox market.The market expansion of monkeypox treatments is supported by increased research and development for the treatment of monkeypox as well as rising global demand for the therapy.

Impact of COVID-19 on the Global Monkeypox Treatment Market

The recent COVID-19 pandemic has resulted in weakened immunity in those affected, which raises the risk of monkeypox virus infection. Monkeypox market expansion was boosted by a large population that was infected with COVID-19. Businesses across all industries are struggling financially as a result of the global lockdown caused by the corona virus (COVID-19) epidemic. Global supply chains and manufacturing operations have been affected as a result of lockdowns imposed by national authorities, travel restrictions, and other COVID-19 safety measures. However, the market for treating monkeypox is barely impacted by COVID-19.However, due to a significant lack of medical supplies and raw materials, manufacturing locations located in the worst-hit nations have been badly impacted. This has disrupted the world's supply chains.The Food and Drug Administration (FDA) of the United States is still keeping tabs on the supply chain. In order to improve the supply chain of medical products in the future, the Center for Drug Evaluation and Research (CDER) Drug Shortage Staff asked manufacturers to assess their entire supply chain of various products, including ethanol, EDTA (Ethylenediaminetetraacetic acid), and vaccine manufacturing equipment, among others.

Scope of the Report:

Report Metric Details

  • Market size available for years: 2019-2032
  • Base year considered: 2021
  • Forecast period: 2022-2032
  • Segments covered: By Treatment, By Product Type, By Dosage Form, By Route of Administration, By Age, By Gender, By Prescription Type, By End User
  • Regions covered: Asia Pacific, Europe, Middle East and Africa, North America, Latin America
  • Companies Covered: Bavarian Nordic, Chimerix, CIDIC Co., Ltd., EMERGENT, Hetero, Olon S.p.A, Piramal Pharma Solutions, SIGA Technologies, Teva Pharmaceutical Industries Ltd.

Global Monkeypox Treatment Market Segmentation:

  • By Treatment: Based on the Treatment, Global Monkeypox Treatment Market is segmented as; Medications (Analgesics, Antipruritic or Anti-itch drugs, Antipyretics, Antivirals), Vaccine (Smallpox Vaccine, JYNNEOS/Imvanex), Vaccinia Immune Globulin (VIG).
  • By Product Type: Based on the Product Type, Global Monkeypox Treatment Market is segmented as; Creams, Gels, Injectable, Ointment, Tablets.
  • By Dosage Form: Based on the Dosage Form, Global Monkeypox Treatment Market is segmented as; Liquid, Semi Solid, Solid.
  • By Prescription Type: Based on the Prescription Type, Global Monkeypox Treatment Market is segmented as; Over the counter (OTC) drugs, Prescription (Rx) drugs.
  • By End User: Based on the End User, Global Monkeypox Treatment Market is segmented as; Hospital Pharmacy, Online Pharmacy, Retail Pharmacy.
  • By Region: Over the forecast period, the monkeypox market in Asia Pacific is anticipated to develop at the quickest rate. Other factors contributing to the market expansion in the region include an increase in the number of patients with monkeypox, government activities to raise public awareness, and an increase in demand for the treatment.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1 Secondary data
    • 2.1.2 Primary data
    • 2.1.3 SPER's internal database
    • 2.1.4 Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1 Top-down and Bottom-up approach
  • 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
    • 4.1.4 Challenges
  • 4.2. COVID-19 Impacts of the Global Monkeypox Treatment Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1 Strengths
    • 5.1.2 Weaknesses
    • 5.1.3 Opportunities
    • 5.1.4 Threats
  • 5.2. PESTEL analysis
    • 5.2.1 Political landscape
    • 5.2.2 Economic landscape
    • 5.2.3 Social landscape
    • 5.2.4 Technological landscape
    • 5.2.5 Environmental landscape
    • 5.2.6 Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining power of Buyers
    • 5.3.3 Threat of Substitute
    • 5.3.4 Threat of new entrant
    • 5.3.5 Competitive rivalry
  • 5.4. Heat map analysis

6. Competitive Landscape

  • 6.1 Global Monkeypox Treatment Manufacturing Base Distribution, Sales Area, Product Type
  • 6.2 Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Monkeypox Treatment Market

7. Global Monkeypox Treatment Market, By Treatment, 2019-2032 (USD Million)

  • 7.1 Medications
    • 7.1.1 Analgesics
    • 7.1.2 Antipruritic or Anti-itch drugs
    • 7.1.3 Antipyretics
    • 7.1.4 Antivirals
  • 7.2 Vaccine
    • 7.2.1 Smallpox Vaccine
    • 7.2.2 JYNNEOS/Imvanex
  • 7.3 Vaccinia Immune Globulin (VIG)

8. Global Monkeypox Treatment Market, By Product Type, 2019-2032 (USD Million)

  • 8.1 Creams
  • 8.2 Gels
  • 8.3 Injectable
  • 8.4 Ointment
  • 8.5 Tablets

9. Global Monkeypox Treatment Market, By Dosage Form, 2019-2032 (USD Million)

  • 9.1 Liquid
  • 9.2 Semi Solid
  • 9.3 Solid

10. Global Monkeypox Treatment Market, By Route of Administration, 2019-2032 (USD Million)

  • 10.1 Oral
  • 10.2 Parenteral
  • 10.3 Topical

11. Global Monkeypox Treatment Market, By Age, 2019-2032 (USD Million)

  • 11.1 Adults
  • 11.2 Geriatrics
  • 11.3 Paediatrics

12. Global Monkeypox Treatment Market, By Gender, 2019-2032 (USD Million)

  • 12.1 Female
  • 12.2 Male
  • 12.3 Others

13. Global Monkeypox Treatment Market, By Prescription Type, 2019-2032 (USD Million)

  • 13.1 Over the counter (OTC) drugs
  • 13.2 Prescription (Rx) drugs

14. Global Monkeypox Treatment Market, By End User, 2019-2032 (USD Million)

  • 14.1 Hospital Pharmacy
  • 14.2 Online Pharmacy
  • 14.3 Retail Pharmacy

15. Global Monkeypox Treatment Market, By Region, 2019-2032 (USD Million)

  • 15.1 Global Monkeypox TreatmentSize and Market Share by Region (2019-2025)
  • 15.2 Global Monkeypox TreatmentSize and Market Share by Region (2026-2032)
  • 15.3 Asia-Pacific
    • 15.3.1 Australia
    • 15.3.2 China
    • 15.3.3 India
    • 15.3.4 Japan
    • 15.3.5 South Korea
    • 15.3.6 Rest of Asia-Pacific
  • 15.4 Europe
    • 15.4.1 France
    • 15.4.2 Germany
    • 15.4.3 Italy
    • 15.4.4 Spain
    • 15.4.5 United Kingdom
    • 15.4.6 Rest of Europe
  • 15.5 Middle East & Africa
    • 15.5.1 Kingdom of Saudi Arabia
    • 15.5.2 United Arab Emirates
    • 15.5.3 Rest of Middle East & Africa
  • 15.6 North America
    • 15.6.1 Canada
    • 15.6.2 Mexico
    • 15.6.3 United States
  • 15.7 Latin America
    • 15.7.1 Argentina
    • 15.7.2 Brazil
    • 15.7.3 Rest of Latin America

16. Company Profiles

  • 16.1 Bavarian Nordic
    • 16.1.1 Company details
    • 16.1.2 Financial outlook
    • 16.1.3 Product summary
    • 16.1.4 Recent developments
  • 16.2 Chimerix
    • 16.2.1 Company details
    • 16.2.2 Financial outlook
    • 16.2.3 Product summary
    • 16.2.4 Recent developments
  • 16.3 CIDIC Co., Ltd.
    • 16.3.1 Company details
    • 16.3.2 Financial outlook
    • 16.3.3 Product summary
    • 16.3.4 Recent developments
  • 16.4 EMERGENT
    • 16.4.1 Company details
    • 16.4.2 Financial outlook
    • 16.4.3 Product summary
    • 16.4.4 Recent developments
  • 16.5 Hetero
    • 16.5.1 Company details
    • 16.5.2 Financial outlook
    • 16.5.3 Product summary
    • 16.5.4 Recent developments
  • 16.6 Olon S.p.A
    • 16.6.1 Company details
    • 16.6.2 Financial outlook
    • 16.6.3 Product summary
    • 16.6.4 Recent developments
  • 16.7 Piramal Pharma Solutions
    • 16.7.1 Company details
    • 16.7.2 Financial outlook
    • 16.7.3 Product summary
    • 16.7.4 Recent developments
  • 16.8 SIGA Technologies
    • 16.8.1 Company details
    • 16.8.2 Financial outlook
    • 16.8.3 Product summary
    • 16.8.4 Recent developments
  • 16.9 Teva Pharmaceutical Industries Ltd.
    • 16.9.1 Company details
    • 16.9.2 Financial outlook
    • 16.9.3 Product summary
    • 16.9.4 Recent developments

17. List of Abbreviations

18. Reference Links

19. Conclusion

20. Research Scope